New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:47 EDTGILDGilead updates on Hepatitis C development programs
Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic hepatitis C virus infection. The company released new results from an arm of the ongoing Phase 2 ELECTRON study examining the nucleotide sofosbuvir and the NS5A inhibitor GS-5885, and provided a progress report on a range of Phase 2 and 3 clinical trials evaluating a once-daily fixed-dose combination tablet of these medicines. Gilead announced full data from one cohort of the ongoing Phase 2 ELECTRON study examining a 12-week course of all-oral therapy with sofosbuvir, GS-5885 and ribavirin among genotype 1 HCV patients who had previously failed to respond to an interferon-containing regimen, or “null responders.” Preliminary data, presented in November at the annual meeting of the American Association for the Study of Liver Diseases, demonstrated that three of nine patients remained HCV RNA undetectable four weeks after completing therapy. Today’s announcement confirms that all nine patients in this cohort achieved SVR4. These patients will continue to be observed to determine sustained virologic response rates at weeks 12 and 24 of follow-up. Results from eight other arms of the ELECTRON study, evaluating sofosbuvir alone and with RBV and/or pegylated IFN, were published earlier this month in the New England Journal of Medicine, the company said. The company also said these updates will be highlighted today as part of Gilead’s corporate presentation at the 31st Annual J.P. Morgan Healthcare Conference taking place in San Francisco. “Since the acquisition of Pharmasset only a year ago, we have fully enrolled four Phase 3 studies of sofosbuvir and during the first quarter of this year we will have initiated two Phase 3 studies of the sofosbuvir and GS-5885 fixed-dose combination,” said Norbert Bischofberger, PhD, Chief Scientific Officer, Gilead Sciences. “We are on track to submit the initial regulatory filing for sofosbuvir by mid-2013 and to file for approval of the fixed-dose combination of sofosbuvir and GS-5885 in 2014.”
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
09:39 EDTGILDActive equity options trading
Subscribe for More Information
November 24, 2014
16:00 EDTGILDOptions Update; November 24, 2014
Subscribe for More Information
10:16 EDTGILDGilead management to meet with ISI Group
Meeting to be held in Scotland on December 1 hosted by ISI Group.
09:39 EDTGILDActive equity options trading
Subscribe for More Information
November 21, 2014
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL AMZN TSLA BIDU CLF DOW LVS BABA TWTR GILD
November 20, 2014
15:44 EDTGILDOptions Update; November 20, 2014
Subscribe for More Information
11:21 EDTGILDGilead calls active on renewed activist investor speculation
Gilead November 101 and 103 calls are active on 14K contracts (2K puts) on renewed activist investor speculation. November call option implied volatility is at 38, December is at 36, and January is at 35; compared to its 26-week average of 33 according to Track Data. Active call volume suggests traders taking positions for larger near term price movement.
11:11 EDTGILDRumor: Gilead moves up on renewed activiest investor speculation
Shares of Gilead are moving higher on speculation that Carl Icahn has taken a stake in the company.
November 19, 2014
07:33 EDTGILDGilead Q4 HCV sales likely to reach at least $3.5B, says Wells Fargo
Subscribe for More Information
November 18, 2014
16:00 EDTGILDOptions Update; November 18, 2014
iPath S&P 500 VIX Short-Term Futures down 48c to 28.09. Option volume leaders: AAPL TSLA TWTR KO PBR GILD according to Track Data.
10:08 EDTGILDGilead granted European Commission marketing authorization for Harvoni
Subscribe for More Information
November 17, 2014
16:00 EDTGILDOptions Update; November 17, 2014
Subscribe for More Information
11:06 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
November 14, 2014
14:53 EDTGILDCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:48 EDTGILDStocks with call strike movement; GILD BBY
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
November 13, 2014
13:32 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use